Adlai Nortye Ltd.

Healthcare · Biotechnology · Cayman Islands

Last price 9.55 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 615.00M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (αPD-L1 x CD86 variant x LAG3 variant) t...